The Analysis Guide adjusts the target price for CombiGene to SEK 21
Here’s how Thomas Nilsson writes in his latest analysis of CombiGene:
As the company’s epilepsy project CG01 enters phase 1/2 studies in 2022, we have recently raised the probability of launch to 15%. As the company enters a more intensive development phase, we have adjusted our cost estimates for 2021 and 2022. We adjust our target price to SEK 21 after the reverse split the company has carried out that reduced the number of outstanding shares to 19.8 million. Our previous target price of SEK 1,5 was based on 229,3 million outstanding shares.
The analysis is only available in Swedish
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.